An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication

Naoko Kanazawa, Kazuaki Matsumoto, Kazuro Ikawa, Tomohide Fukamizu, Akari Shigemi, Keiko Yaji, Yoshihiro Shimodozono, Norifumi Morikawa, Yasuo Takeda, Katsushi Yamada

研究成果: Article

15 引用 (Scopus)

抄録

Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (≥13 μg/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was <2 μg/mL). Each AUC was estimated using individual dose, creatinine clearance (CL cr), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 μg h/mL for AUC from zero to 24 h (AUC0-24 h). Using published population pharmacokinetic parameters, the dose required to achieve the AUC0-24 h target was calculated as dose (mg) = 750 × (0.00498 × CLcr (mL/min) + 0.00426 × body weight (kg). For various combinations of CLcr and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.

元の言語English
ページ(範囲)297-300
ページ数4
ジャーナルJournal of Infection and Chemotherapy
17
発行部数2
DOI
出版物ステータスPublished - 2011 4
外部発表Yes

Fingerprint

Teicoplanin
Methicillin-Resistant Staphylococcus aureus
Nomograms
Area Under Curve
Body Weight
Serum
Glycopeptides
Drug Monitoring
Half-Life
Creatinine
Software
Pharmacokinetics
Logistic Models
Regression Analysis
Anti-Bacterial Agents
Infection
Population

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. / Kanazawa, Naoko; Matsumoto, Kazuaki; Ikawa, Kazuro; Fukamizu, Tomohide; Shigemi, Akari; Yaji, Keiko; Shimodozono, Yoshihiro; Morikawa, Norifumi; Takeda, Yasuo; Yamada, Katsushi.

:: Journal of Infection and Chemotherapy, 巻 17, 番号 2, 04.2011, p. 297-300.

研究成果: Article

Kanazawa, N, Matsumoto, K, Ikawa, K, Fukamizu, T, Shigemi, A, Yaji, K, Shimodozono, Y, Morikawa, N, Takeda, Y & Yamada, K 2011, 'An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication', Journal of Infection and Chemotherapy, 巻. 17, 番号 2, pp. 297-300. https://doi.org/10.1007/s10156-010-0105-1
Kanazawa, Naoko ; Matsumoto, Kazuaki ; Ikawa, Kazuro ; Fukamizu, Tomohide ; Shigemi, Akari ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Morikawa, Norifumi ; Takeda, Yasuo ; Yamada, Katsushi. / An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. :: Journal of Infection and Chemotherapy. 2011 ; 巻 17, 番号 2. pp. 297-300.
@article{af9ef9d3ada84aceb5785dee9cd527cd,
title = "An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication",
abstract = "Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (≥13 μg/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was <2 μg/mL). Each AUC was estimated using individual dose, creatinine clearance (CL cr), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 μg h/mL for AUC from zero to 24 h (AUC0-24 h). Using published population pharmacokinetic parameters, the dose required to achieve the AUC0-24 h target was calculated as dose (mg) = 750 × (0.00498 × CLcr (mL/min) + 0.00426 × body weight (kg). For various combinations of CLcr and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.",
keywords = "AUC, Loading dose, Methicillin-resistant Staphylococcus aureus (MRSA), Nomogram, Teicoplanin",
author = "Naoko Kanazawa and Kazuaki Matsumoto and Kazuro Ikawa and Tomohide Fukamizu and Akari Shigemi and Keiko Yaji and Yoshihiro Shimodozono and Norifumi Morikawa and Yasuo Takeda and Katsushi Yamada",
year = "2011",
month = "4",
doi = "10.1007/s10156-010-0105-1",
language = "English",
volume = "17",
pages = "297--300",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication

AU - Kanazawa, Naoko

AU - Matsumoto, Kazuaki

AU - Ikawa, Kazuro

AU - Fukamizu, Tomohide

AU - Shigemi, Akari

AU - Yaji, Keiko

AU - Shimodozono, Yoshihiro

AU - Morikawa, Norifumi

AU - Takeda, Yasuo

AU - Yamada, Katsushi

PY - 2011/4

Y1 - 2011/4

N2 - Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (≥13 μg/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was <2 μg/mL). Each AUC was estimated using individual dose, creatinine clearance (CL cr), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 μg h/mL for AUC from zero to 24 h (AUC0-24 h). Using published population pharmacokinetic parameters, the dose required to achieve the AUC0-24 h target was calculated as dose (mg) = 750 × (0.00498 × CLcr (mL/min) + 0.00426 × body weight (kg). For various combinations of CLcr and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.

AB - Teicoplanin is a glycopeptide antibacterial agent that has a long serum half-life and therefore takes time to achieve steady-state conditions. An appropriate initial dosing is needed for teicoplanin to promptly reach an effective serum trough concentration. However, little information is available on tailoring the initial dosing for patients with various characteristics. The objective of this study was to develop a nomogram for determining teicoplanin initial dose to promptly reach an effective trough concentration (≥13 μg/mL). A logistic regression analysis was performed to test whether the area under the concentration time curve (AUC) is a significant predictor of microbiological response (persistence 0; eradication 1). The study included 24 adult patients with methicillin-resistant Staphylococcus aureus infections [minimal inhibitory concentration (MIC) for the isolates was <2 μg/mL). Each AUC was estimated using individual dose, creatinine clearance (CL cr), and body weight data. The target value, which gives about a 0.9 microbiological eradication probability, was 750 μg h/mL for AUC from zero to 24 h (AUC0-24 h). Using published population pharmacokinetic parameters, the dose required to achieve the AUC0-24 h target was calculated as dose (mg) = 750 × (0.00498 × CLcr (mL/min) + 0.00426 × body weight (kg). For various combinations of CLcr and body weight, we checked the calculated doses using a therapeutic drug monitoring (TDM)-supporting software and developed a nomogram. The nomogram would be useful for initial dose adjustment to promptly reach an effective serum trough concentration and avoid adverse events of teicoplanin.

KW - AUC

KW - Loading dose

KW - Methicillin-resistant Staphylococcus aureus (MRSA)

KW - Nomogram

KW - Teicoplanin

UR - http://www.scopus.com/inward/record.url?scp=79955886296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955886296&partnerID=8YFLogxK

U2 - 10.1007/s10156-010-0105-1

DO - 10.1007/s10156-010-0105-1

M3 - Article

C2 - 20714913

AN - SCOPUS:79955886296

VL - 17

SP - 297

EP - 300

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 2

ER -